Introduction
Human CMV (HCMV) remains a major cause of morbidity and mortality after allo-SCT. HCMV-seropositive or -seronegative patients receiving a transplant from a seropositive donor are at risk to reactivate latent virus during intense immunosuppression following SCT. More recently, preemptive antiviral therapy based on various diagnostic assays has become a standard of care in many centers. Patients at risk are screened weekly for HCMV reactivation, and antiviral therapy is started in patients showing a positive test result. In two major prospective randomized studies, preemptive therapy based on a positive culture from either a bronchoalveolar lavage collected on day 35 after transplant, 1 or from blood, urine or throatwashing samples collected weekly, 2 was demonstrated to significantly reduce HCMV disease. However, owing to the poor sensitivity of the culture method, 10-15% of the study patients developed HCMV disease. Therefore, diagnostic tests with a higher sensitivity such as PCR and the pp65 antigen assay have been developed as screening tests. [3] [4] [5] [6] [7] [8] [9] Our group could demonstrate PCR-based antiviral therapy to be superior to culture-based therapy, with respect to rate of HCMV disease, HCMV-related mortality and OS at day 100 after transplant. 3 However, this improvement is associated with an overtreatment of at least 50% of the patients with potentially toxic antiviral compounds. 10 Different diagnostic strategies to improve patient stratification for preemptive antiviral therapy have been proposed, 11 including measurement of viral-load kinetics, 12 and assessment of active viral replication by the detection of HCMV RNA in clinical samples. 13 More recently, a new diagnostic method based on the amplification of HCMV RNA in blood samples has been commercialized (NucliSens CMV pp67, bioMerieux bv, Boxtel, the Netherlands). As this assay was shown to demonstrate high sensitivity and specificity, 14, 15 we initiated a prospective multicenter randomized study comparing HCMV DNA-and HCMV RNA-based preemptive antiviral therapy in patients at high risk for HCMV disease following allo-SCT.
Patients and methods

Study design
This study was designed as a prospective randomized controlled pilot trial to determine the safety and efficacy of preemptive therapy of HCMV infection in human SCT recipients, based on determination of HCMV pp67 mRNA in blood compared to the currently performed antiviral therapy based on a confirmed positive PCR result. The primary end point of this study was safety as defined by the occurrence of HCMV disease in both study arms. Secondary end points were total and average number of anti-HCMV treatment days, average duration of first and additional antiviral treatment per patient, incidence of lateonset HCMV disease and OS at day 100 after transplant.
In equal proportions, patients were randomized at the time of transplantation to receive antiviral therapy based on either HCMV pp67 mRNA or DNA-PCR. Patients were stratified for center, donor type (unrelated and mismatched family donor vs HLA-identical family member) and recipient HCMV serostatus, ensuring an equal balance of risk factors across the two study arms.
Three different clinically well-established DNA-PCR methods for early detection of HCMV infection following allo-SCT were compared to the commercialized and standardized pp67 mRNA assay at the participating centers. The assay applied in Stockholm was previously compared with the assay in Tuebingen, and shown to have slightly higher sensitivity. Both assays are able to detect approximately 10-100 CMV copies per ml of blood, and the differences in the study reported by Grundy et al. 16 were not found to be clinically relevant. The assay in the third participating center in Rochester has been reported to have a similar sensitivity range. Comparable levels of PCR positivity have been reported for this study arm between centers (22 of 35 in Tuebingen, 19 of 24 in Huddinge and 3 of 7 in Rochester). On the basis of these facts, a comparable sensitivity of the PCR assay has been assumed for the purpose of this study.
After inclusion of 20 patients in each study arm, an interim analysis was performed. According to predefined study rules with a single-sided confidence interval of 95%, the study was planned to be closed if among the first 20 patients in the investigational arm (pp67-based preemptive therapy) X4 patients did develop HCMV disease. No safety concerns were demonstrated.
Patients
In all, 133 patients at risk to develop HCMV infection after allo-SCT were included in this prospective study between November 1999 and February 2002. Three patients were excluded from the analysis (HCMV serostatus D-/R-, n ¼ 1; autologous SCT, n ¼ 1; death before transplantation, n ¼ 1). Thus, 130 patients were evaluable for final analysis. Patients were allowed to be included into the study protocol if they were undergoing allo-SCT, had a positive HCMV serology and/or received a graft from an HCMVseropositive stem cell donor, and had agreed with, and signed the written informed consent form. Subjects o18 years of age had to have the written informed consent of a parent or guardian. Patient characteristics at the time of transplant are shown in Table 1 . The following patients were excluded from the study: HCMV-seronegative patients receiving a transplant from a HCMV-seronegative donor, patients presenting concurrently with other neoplastic diseases requiring systemic cytotoxic or radiation therapy, subjects with unstable or severe intercurrent medical conditions, interfering with their ability to complete the study, and patients receiving systemic antiviral prophylaxis for HCMV infection. CMV-negative or leukodepleted blood was used for the transfusion of seronegative recipients.
Collection of blood specimens EDTA-anticoagulated whole blood and heparinized blood samples were collected through the central line once weekly starting from day 14 until day 100 after transplantation. In case of active HCMV infection, at the end of the follow-up PCR-based vs late mRNA-based anti-HCMV therapy H Hebart et al period, viral monitoring was extended until HCMV infection had disappeared. Whole blood samples were transported to the laboratory on the day of the phlebotomy and nucleic acid extraction was immediately started (see below). Patients randomized in the DNA-PCR arm were also tested for pp67 mRNA positivity, and patients in the NucliSens arm were tested for DNA-PCR. The two assays were performed in parallel on freshly collected blood samples. Treatment was initiated according to the assay to which patients were randomized to, and results of the comparator tests were blinded to the clinicians to exclude any impact on clinical decision-making.
NASBA
Nucleic acid sequence-based amplification (NASBA) assay was carried out according to the manufacturer's instructions (bioMerieux bv). Briefly, 0.1 mL of heparinized or EDTA-anticoagulated blood was mixed thoroughly with 0.9 mL of NASBA lysis buffer (4.7 M guanidinium thiocyanate, 46 mM Tris (pH 6.4), 20 mM EDTA, 1.2% (wt/vol) Triton X-100), and the mixture was stored at 70 1C. A standardized amount of system control RNA, which served as a positive control for the isolation, amplification and detection of RNA during the assay procedure, was added before silica-based nucleic acid isolation, 17 which was performed essentially as described by Boom et al. 18 The nucleic acids were finally eluted in 50 mL of 1.0 mM Tris (pH 8.5). The NASBA amplification reaction was performed with two primers, which were designed to amplify part of the mRNA encoding HCMV pp67 (the UL 65 gene product). NASBA reactions were performed as previously described 19 in a 20 mL reaction mixture containing 40 mM Tris (pH 8.5), 12 mM MgCl 2 , 70 mM KCl, 15% (vol/vol) dimethyl sulfoxide, 5 mM dithiothreitol, each deoxynucleoside triphosphate at a concentration of 1 mM, ATP, CTP, and UTP each at a concentration of 2 mM, 1.5 mM GTP, 0.5 mM ITP, 2 mg of BSA, 0.08 U of RNase H, 32 U of T7 RNA polymerase, 6.4 U of avian myeloblastosis reverse transcriptase, each primer at a concentration of 0.2 mM, and 5 mL of isolated nucleic acids. Before the addition of the enzymes, the NASBA reaction mixtures were incubated for 5 min at 65 1C to destabilize the secondary RNA structures and subsequently cooled down to 41 1C to allow primer annealing. After the addition of the enzymes, the reaction mixtures were incubated at 41 1C for 90 min. Detection of the specific amplification product and internal control was performed using electrochemiluminescent bead-based system and the signal was measured using the NucliSens Reader (bioMerieux bv).
PCR PCR was performed according to locally established PCR protocols. In Tuebingen, 100 ng of DNA from whole blood was added to the PCR reaction mixture and a 147-bp DNA fragment amplified between position 1767 and 1913 of the fourth exon of the immediate early gene of the HCMV strain AD169 using specific primers. 20 In all assays 0.1, 1, 10 and 100 fg of cloned HCMV DNA fragment pCM5018 were amplified. Amplicons were detected using the slot blot technique with a digoxigenin-labeled probe specific for HCMV and anti-digoxigenin antibodies, conjugated with alkaline phosphatase (Roche, Mannheim, Germany). 21 PCR results were available within 1 day.
In Stockholm, leukocytes were isolated from 10 mL of peripheral blood and DNA extracted. The primer pair amplified a 723-bp fragment of the forth exon of the immediate early 1 gene. A nested PCR was used to amplify a second PCR product of 164 bp. Amplicons were detected using an ethidium bromide staining of an agarose gel. PCR was run twice weekly and results were available on the next day. 22 In Rochester, viral nucleic acid was extracted from peripheral blood leukocytes using the Isoquick extraction method (Orca Research Inc., Bothell, WA, USA). HCMV PCR was performed using oligonucleotide primers and probes that amplify and detect the HindIII-X fragment region (406 bp). The amplified PCR products were detected using a PCR ELISA kit (Roche), according to manufacturer's instructions. The details of this qualitative HCMV PCR assay have been previously described. 21 This PCR assay has previously been validated clinically for the preemptive therapy of HCMV infection in transplant patients. 23 Definitions of HCMV infection and disease All patients tested positive by nucleic acid amplification were considered to be actively infected by HCMV.
HCMV disease was diagnosed by the following criteria. 24 HCMV pneumonia: dyspnea, interstitial infiltrates on the chest radiograph, plus detection of HCMV in bronchial washings or lung biopsies. HCMV enteritis: gastrointestinal symptoms, mucosal lesions on endoscopy, plus demonstration of HCMV. HCMV hepatitis: abnormal liver function tests, absence of any other cause of hepatitis and detection of HCMV in the liver biopsy. Detection of HCMV was performed by virus isolation, histopathological testing, immunohistochemical analysis and in situ hybridization.
Therapy for HCMV infection and disease
In the NucliSens arm, patients were treated at the first pp67 mRNA positive test result for a minimum of 2 weeks. If the assay showed persistence of HCMV after these 2 weeks, treatment was continued on a maintenance dose. 25 Persistence of HCMV activity after 4 weeks resulted in shifting from first-line treatment to second-line treatment. Recurrent episodes of active infection were treated with additional courses of antiviral therapy starting when pp67 mRNA had become positive again, for at least 2 weeks or until documented pp67 mRNA negativity. In the control PCR arm, patients were treated identically, but initiation of antiviral therapy was based on a confirmed DNA-PCR assay (two consecutive positive results). Preemptive therapy consisted of i.v. ganciclovir (dosage 2 Â 5 mg/kg body weight per day) or foscarnet (dosage 2 Â 60 mg/kg body weight per day). Patients with documented HCMV disease received combination therapy with i.v. ganciclovir and HCMV-hyperimmunoglobulin. Maintenance therapy with i.v. ganciclovir (6 mg/kg/day) five times weekly or foscarnet (90 mg/kg/day) five times weekly was administered only when the screening test remained positive after a 14-day course of antiviral therapy.
Statistical analysis
Data were analyzed as of 11 February 2005. The survival curve in the two randomization arms was determined by the Kaplan-Meier method used in analyzing data with GraphPad Prism (GraphPad Software, San Diego, CA, USA). Differences in medians and percentages were tested using the Fisher's exact test. Mann-Whitney test was performed to compare two unpaired groups in each randomization arm and the two randomization arms themselves. P-values o0.05 were considered statistically significant; P-values 40.05 were expressed as NS. All tests were two tailed.
Results
Diagnosis of HCMV infection
Altogether, 64 of 130 patients were randomized to weekly HCMV screening by pp67 mRNA (group 1) and 66 by HCMV PCR (group 2). Major risk factors for HCMV infection and disease were balanced between both groups ( Table 1 ). The only detectable difference between groups was a higher number of patients receiving BM as stem cell source in the pp67 mRNA screened cohort (29 of 64 vs 13 of 66). In all, 41 out of 64 patients (64.1%) in group 1 and 44 out of 66 patients (66.7%) in group 2 were found to be HCMV infected as defined by the assigned screening assay. Forty-four patients assigned to group 1 were tested HCMV DNA-PCR positive (67.7%) and 33 patients assigned to group 2 pp67 were tested mRNA positive (50%). Cumulative HCMV first detection rate using NASBA was comparable to detection rates using the established confirmed PCR method (Figure 1a ; log-rank test: 
, which is consistent with the lower sensitivity of the NASBA assay. There was no difference in the incidence of HCMV infection, as defined by the two assays, when patients transplanted from an HLA-identical sibling donor were compared with patients transplanted from an alternative donor (Table 2 ). HCMV seronegativity of the recipient was associated with a lower risk for HCMV infection in both group 1 (P ¼ 0.001) and 2 (P ¼ 0.09) ( Table 3) . As a consequence, within this group, there were fewer patients receiving preemptive antiviral therapy based on nucleic acid testing (P ¼ 0.01).
A total of 1427 blood samples were analyzed by NASBA and 1409 by DNA-PCR. Overall, the number of NASBA- Figure 1 Cumulative HCMV first detection rates using NASBA and (confirmed vs single positive) PCR techniques. Significant differences were observed in the cumulative detection rates when considering a single positive PCR result (a; log-rank test, P ¼ 0.002), whereas similar results were obtained when NASBA was compared with confirmed PCR results (b; log-rank test, P ¼ 0.321). In group 1, HCMV infection was diagnosed by NASBA at a median of 37 (range 4-93) days, and in group 2, by DNA-PCR at a median of 21 (range 1-76) days after transplantation (P ¼ 0.0054), indicating a lower sensitivity of the pp67 mRNA detection method. The lower sensitivity of the NASBA assay was confirmed by comparison with a semiquantitative PCR assay in 689 samples, 130 (18.9%) out of which were found positive by NASBA and 251 (36.4%) by DNA-PCR. In the majority of NASBAnegative, DNA-PCR-positive samples, a low viral load between 0.1 and 1 fg/mL target DNA was documented (90.6%), whereas in samples detected as positive by both NASBA and DNA-PCR, the viral load was higher (X1 fg/mL in 89.1%) (data not shown).
Preemptive antiviral therapy
According to the study design, antiviral treatment was initiated at the time of the first positive pp67 mRNA result (group 1), or at the second consecutive positive DNA-PCR result (group 2). Overall, 42 patients from group 1 and 39 patients from group 2 received antiviral therapy. In a subgroup of patients, antiviral therapy was either given too early for severe GVHD and/or suspected CMV infection (group 1, n ¼ 1; group 2, n ¼ 7), or too late for clinically nonrelevant low-level viremia (group 1, n ¼ 5; group 2, n ¼ 5), based on clinical decision-making. There was no difference between the two groups in the time delay of assigned treatment.
Antiviral therapy was initiated at a median of 37.5 (range 7-85) days in group 1 and 32 (range 14-87) days in group 2 (P ¼ NS). The median duration of antiviral therapy during the first antiviral treatment episode was 19 (range 2-148) days in group 1 and 28 (range 4-80) days in group 2 (Po0.02) ( Table 4) . A second viremic episode after successful clearance of HCMV during the first treatment episode was detectable in 16 patients in group 1, and respectively 10 patients in group 2 (P ¼ 0.25). Antiviral retreatment was initiated in 15 out of 16 patients in group 1 and 8 out of 10 patients in group 2, with no difference in the median treatment duration (18 (range 6-82) vs 15 (range 8-30) days). The overall duration of antiviral therapy was 23 (range 2-149) days in group 1, and 29 (range 4-80) days in group 2 (P ¼ NS). Table 4 Preemptive therapy in the two randomization arms of the whole transplant patient population and the two subgroups of HSCT recipients from UD and sibling
Parameter
Total patient population in the randomization arm
Pvalue a
HSCT from UD in the randomization arm
HSCT from sibling in the randomization arm
(n ¼ 64) HCMV disease and OS OS was not different between both groups on days 100 (Figure 2 ; log-rank test: P ¼ 0.9117; Wilcoxon test: P ¼ 0.8412) and 180 after transplantation. In group 1, one patient developed HCMV interstitial pneumonia and one developed HCMV gastrointestinal disease, whereas in group 2, four patients developed HCMV disease (interstitial pneumonia, n ¼ 1; gastrointestinal disease, n ¼ 2; retinitis, n ¼ 1 patient). Late-onset HCMV disease (occurring after day 100) was diagnosed in two patients of group 1 and in one patient of group 2. All 6 died of causes not directly related to HCMV. Causes of death were invasive aspergillosis (n ¼ 3), bacterial infections (n ¼ 2) or respiratory failure (n ¼ 1). Our data suggest, that the NASBA assay might demonstrate a comparable sensitivity even in high-risk patients after allo-SCT (95% confidence interval for the incidence rate of 6% (4 of 66): 1.7o6o14.8%); however, larger studies need to be performed in the future to conclusively assess noninferiority for the NASBA assay in this setting.
Discussion
With the introduction of antiviral prophylaxis 26 and preemptive antiviral therapy based on sensitive detection methods, the incidence of HCMV disease and HCMVrelated mortality soon after transplantation has been decreased. 3, 27 However, in-house PCR and antigenemia assays are currently in use in most centers, impeding intercenter result comparison, and overall procedure standardization. More recently, a standardized assay detecting the UL65-encoded mRNA was commercialized, but its performance and safety have not been analyzed in a prospective study.
We initiated a prospective pilot study to estimate the clinical utility of the NucliSens CMV pp67 assay vs DNA-PCR testing as a guiding diagnostic tool for initiation and monitoring of preemptive antiviral therapy in allo-SCT recipients. The primary end point of the study was the development of HCMV disease; overall, 6 out of 130 patients developed early HCMV disease; 2 had been randomized to NucliSens-based (n ¼ 64) and 4 to the PCR-based (n ¼ 66) antiviral therapy. The overall incidence of HCMV disease in both groups was low, and larger cohorts would be required for a definitive noninferiority statistical analysis for the NASBA assay. The number of patients developing late-onset HCMV disease (after day 100) was comparable between the two study arms (2 vs 1). In addition, the number of patients with culture-proven viremia, a well-established risk factor for subsequent development of HCMV disease, was also similar (11 vs 10). Moreover, OS was found to be identical between both study groups further underscoring the safety of both treatment strategies. Our data support prospective screening by the NucliSens pp67 assay to be as safe as the conventional PCR screening approach in patients at high risk for the development of HCMV disease following allo-SCT, although larger numbers of patients need to be screened to validate these results.
The number of patients identified as HCMV infected by the assigned screening assay was not found to be different between the two treatment groups, and thus also the number of patients receiving antiviral treatment was not different. Interestingly, duration of antiviral therapy was shorter during the first treatment course in patients receiving antiviral therapy based on a positive NucliSens assay (19 vs 28 days, P ¼ 0.018). However, because of a higher number of patients receiving antiviral treatment for a subsequent episode of HCMV infection (that is, relapse of HCMV infection) following the successful control of the first episode (15 vs 8) , the overall duration of antiviral therapy was not different between both the groups. The shorter duration of antiviral therapy in NucliSens-monitored patients is because of a lower sensitivity of the NASBA assay in samples with a low viral load. Thus, the overall number of NucliSens-positive blood samples in both treatment arms (NucliSens þ samples 254 of 1427, PCR þ samples 515 of 1409) was lower. In addition, fewer patients receiving PCR-based therapy developed a positive NucliSens test as a consequence of early initiation of antiviral therapy at low viral loads. Despite the lower analytical sensitivity of the NucliSens when compared with in-house PCR assays, our strategy to initiate antiviral therapy at the first positive NucliSens assay was found to be safe in clinical practice.
NucliSens-based antiviral therapy in a pediatric population following allo-SCT was found to be as safe as antigenemia-based therapy. 28 In contrast to our study, a more sensitive NucliSens assay targeting HCMV immediate-early mRNA was applied. Not surprisingly, the incidence of HCMV infection as well as the percentage of treated patients was higher in NucliSens-treated compared with antigenemia-treated patients. PCR-based vs late mRNA-based anti-HCMV therapy H Hebart et al
In conclusion, our study indicates that HCMV-directed late mRNA-based antiviral therapy may show comparable safety and efficacy as compared with PCR-based therapy in a prospective study in patients at high risk for HCMV disease following allo-SCT.
